Mubadala Investment Company has launched Mubadala Bio, a life sciences enterprise aimed at bolstering the United Arab Emirates’ pharmaceutical sector, enhancing health outcomes, and propelling economic diversification. The announcement precedes the company’s participation in the Make it in the Emirates 2025 initiative.
Mubadala Bio is set to concentrate on national drug security, expanding access to essential therapeutics and medical devices, and fostering a knowledge-based economy. This move aligns with the UAE’s broader strategy to establish itself as a global leader in life sciences and reduce reliance on imported pharmaceuticals.
The establishment of Mubadala Bio complements Mubadala’s previous strategic investments in the sector. Notably, the acquisition of KELIX bio, a specialty pharmaceutical firm, has been instrumental in expanding the UAE’s biopharma capabilities. KELIX bio has since acquired several assets, including DiabTec LLC, enhancing local manufacturing of critical treatments such as insulin analogues, which are vital for managing diabetes—a prevalent condition in the region.
Mubadala’s collaboration with National Resilience, Inc. aims to develop a biopharma manufacturing facility in Abu Dhabi. This facility is poised to be the first of its kind in the region, focusing on the production of complex biologics to treat diseases like cancer and autoimmune disorders, thereby strengthening the UAE’s position in the global pharmaceutical landscape.
In addition to infrastructure development, Mubadala has partnered with Khalifa University to advance biopharmaceutical research and development. This collaboration focuses on areas such as oncology, metabolic disorders, and genome-based therapeutics, contributing to the UAE’s goal of becoming a hub for medical innovation.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
